Hitachi, Ltd.

Nordson Corporation

Sumitomo Bakelite Company Limited

Kureha Corporation

Astellas Pharma Europe Ltd.

Hikaru Saito

Masaharu Kiyama

Midori Kato

Guangbin Zhou

Daisuke Suzuki

Masafumi Matsunaga

Hiroko Hanzawa

Shizu Takeda

Wataru Kakuta

Toru Yakabe

Haruo Okubo

Ryohei Tsukada

Kunio Ohyama

Hirotaka Hoshi

Yoshiyuki Murakami

Motoyuki Uchida

A culture vessel that can suppress foaming in a culture medium when a common nozzle is used to supply a liquid culture medium and a gas together. This culture vessel includes: a vessel body having an opening portion that communicates with a housing space; a lid that closes the opening portion; and a nozzle that passes through the and extends to the housing space, and supplies a liquid culture medium and a gas together. The nozzle has a vent opening portion that is formed so as to open in a side of the nozzle and serves as a movement path of the gas from inside of the nozzle into the housing space.

Culture vessel and cell culture device

A liquid feed device that feeds a liquid medium and a cell suspension to target containers by respectively suited liquid feed methods is provided. A pumpis connected between a first liquid bottlecontaining a liquid medium and a second liquid bottlecontaining a cell suspension, and a receptacleto be used as a culture container is connected downstream of a second liquid bottle. The liquid medium in the first liquid bottle is sent to the receptacle through the pumpand a branch pointby opening a first supply valve, and the cell suspension in the second liquid bottle is sent to the receptacle by opening a first gas introducing valve, a second gas introducing valve, and a second supply valveand transferring, by pressure, a gas supplied from the first gas introducing valveto the second liquid bottle through the pumpand a branch point

Liquid feed device, and cell culture device and method using same

A liquid delivery device includes a first and second container for a first and second liquid; a third container for receiving a first and second liquid; a fourth container into which a first and second liquid are discharged; a fifth container for a third liquid; a first liquid delivery tube for delivering a first liquid; a second liquid delivery tube for delivering a second liquid; a third liquid delivery tube connected to the first and second liquid delivery tube; a first liquid delivery pump on the third liquid delivery tube; a fourth liquid delivery tube for discharging a first liquid contained in the third container and delivering a third liquid to the third container; a fifth liquid delivery tube connected to the fourth liquid delivery tube; a sixth liquid delivery tube connected to the fourth liquid delivery tube; and a second liquid delivery pump on the fourth liquid delivery tube.

Liquid delivery device and cell culture device using the same

A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.

Composition of tiacumicin compounds

Provided is a pharmaceutical composition for treating cancer and asthma. The object can be solved by a pharmaceutical composition comprising a siRNA molecule that directs cleavage of mRNA of mucin subtype 5 AC via RNA interference, or an antibody against mucin subtype 5AC as an active ingredient. According to the pharmaceutical composition of the present invention, diseases involving an overexpression of mucin subtype 5 AC can be treated efficiently. In particular, the pharmaceutical composition comprising a siRNA molecule of the present invention is effectively used in the treatment of a cancer, particularly pancreatic cancer. In addition, the siRNA or the antibody of the present invention can inhibit the expression or function of MUC5AC, thereby preventing or treating the symptoms of asthma effectively.

Pharmaceutical composition for treatment of cancer and asthma

An improved powder particle supply and transport apparatus and method include a hopper filled with powder particles, an ejection chamber spaced from the hopper and a movable conveying member with a plurality of cavities formed therein. During operation, the conveying member moves the cavities between the hopper and the chamber, and the cavities are filled with powder particles at the hopper and emptied of powder particles at the chamber. An ejector nozzle sprays pressurized air into the chamber toward an aligned outlet, thereby to: 1) create negative pressure in the chamber to draw powder particles from the cavities as the cavities are moved therethrough; and 2) transport powder particles through the outlet to a spray gun. Additional structure may be used to assure complete powder filling of the cavities at the hopper and/or complete powder emptying of the cavities in the chamber. The invention achieves supply and transport of uniform and stable quantities of powder particles to a spray gun, even over very small units of time, regardless of powder particle size and/or cohesive properties.

Apparatus and method for supply and transport of powder particles

Growing community of inventors

Tokyo, Japan

Hikaru Saito